15 Days Price Change
Closing In
WEBSITE Inc. Year: 2012 Industry: Pharmaceuticals & Drugs Listed Page
Buy unlisted shares early and participate in the growth before public listing.
Company Promoters
Pre Issue Share Holding 73.13%
Post Issue Share Holding 53.67%
Listing Price: 283.77420234524
Listing Gain: 50.67%
Current Price: 470
Gain On Issue: 470 | 0%
GMP: --
GMP %: -- %
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1000 | 140,000 |
| Retail (Max) | 1 | 1000 | 140,000 |
| S-HNI (Min) | 2 | 2000 | 280,000 |
| S-HNI (Max) | 7 | 7000 | 980,000 |
| B-HNI (Min) | 8 | 8000 | 1,120,000 |
1. To Set up a plant at Navagam Kheda for manufacturing Croscarmellose Sodium (& amp amp amp amp amp quot CCS& amp amp amp amp amp quot ), Sodium Starch Glycolate and Carboxymethylcellulose (CMC) 2. General Corporate Expenses.
| Category | Nos | Bid | Bid (x) |
|---|---|---|---|
| QIB | 2800000 | 331744000 | 118.5x |
| NII | 1960000 | 1130332000 | 576.7x |
| Retail | 840000 | 344358000 | 410x |
| EMP | 0 | 0 | 0x |
| Total | 5600000 | 2029496000 | 362.4x |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 133 | 166 | 197 | 245 | 265 | |
| Other Income | 2 | 2 | 2 | 4 | 6 | |
| Total Income | 135 | 168 | 200 | 249 | 271 | |
| Total Expenditure | 122 | 153 | 178 | 206 | 223 | |
| Operating Profit | 13 | 15 | 21 | 43 | 48 | |
| Interest | 3 | 3 | 3 | 1 | 0 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | -1 | 0 | |
| Profit Before Tax | 6 | 8 | 15 | 37 | 44 | |
| Provision for Tax | 1 | 2 | 3 | 6 | 11 | |
| Profit After Tax | 5 | 6 | 12 | 30 | 33 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 5 | 6 | 12 | 30 | 33 | |
| Adjusted Earnings Per Share | 3.7 | 1.5 | 9.5 | 14.3 | 15.7 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 27 | 32 | 50 | 164 | 195 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 18 | 7 | 5 | 1 | 1 |
| Other Non-Current Liabilities | 1 | 2 | 1 | 2 | 2 |
| Total Current Liabilities | 35 | 54 | 56 | 46 | 52 |
| Total Liabilities | 81 | 95 | 113 | 213 | 250 |
| Fixed Assets | 30 | 30 | 31 | 29 | 48 |
| Other Non-Current Assets | 1 | 1 | 2 | 12 | 26 |
| Total Current Assets | 50 | 64 | 80 | 172 | 176 |
| Total Assets | 81 | 95 | 113 | 213 | 250 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 0 | 1 | 0 | 2 |
| Cash Flow from Operating Activities | 5 | 15 | 8 | 11 | 25 |
| Cash Flow from Investing Activities | -6 | -4 | -4 | -82 | -9 |
| Cash Flow from Financing Activities | -2 | -10 | -4 | 72 | -14 |
| Net Cash Inflow / Outflow | -3 | 1 | -1 | 1 | 2 |
| Closing Cash & Cash Equivalent | 0 | 1 | 0 | 2 | 4 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.72 | 1.52 | 9.45 | 14.34 | 15.71 |
| CEPS(Rs) | 6.48 | 2.59 | 12.62 | 16.44 | 17.71 |
| DPS(Rs) | 1 | 0.8 | 0.8 | 1 | 1 |
| Book NAV/Share(Rs) | 20.64 | 8.29 | 38.92 | 77.86 | 92.55 |
| Core EBITDA Margin(%) | 8.06 | 7.83 | 9.61 | 16.08 | 15.84 |
| EBIT Margin(%) | 7.08 | 6.43 | 8.79 | 15.35 | 16.67 |
| Pre Tax Margin(%) | 4.53 | 4.58 | 7.5 | 14.88 | 16.54 |
| PAT Margin (%) | 3.62 | 3.56 | 6.2 | 12.29 | 12.5 |
| Cash Profit Margin (%) | 6.3 | 6.06 | 8.28 | 14.09 | 14.09 |
| ROA(%) | 5.95 | 6.72 | 11.77 | 18.47 | 14.27 |
| ROE(%) | 18.04 | 20.07 | 29.67 | 28.17 | 18.44 |
| ROCE(%) | 16.38 | 18.78 | 26.79 | 30.16 | 23.66 |
| Receivable days | 34.72 | 32.66 | 43.85 | 62.56 | 81.86 |
| Inventory Days | 86.87 | 78.34 | 75.42 | 55.7 | 45.95 |
| Payable days | 74.35 | 78.01 | 98.79 | 67.39 | 42.62 |
| PER(x) | 0 | 0 | 0 | 16.21 | 11.49 |
| Price/Book(x) | 0 | 0 | 0 | 2.99 | 1.95 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.41 | 0.52 |
| EV/Net Sales(x) | 0.25 | 0.21 | 0.17 | 1.86 | 1.33 |
| EV/Core EBITDA(x) | 2.59 | 2.31 | 1.57 | 10.61 | 7.29 |
| Net Sales Growth(%) | 0 | 25 | 19.05 | 24.45 | 7.77 |
| EBIT Growth(%) | 0 | 13.58 | 62.67 | 117.36 | 17.07 |
| PAT Growth(%) | 0 | 22.7 | 107.57 | 146.63 | 9.6 |
| EPS Growth(%) | 0 | -59.1 | 520.77 | 51.7 | 9.6 |
| Debt/Equity(x) | 1.15 | 0.75 | 0.45 | 0.08 | 0.01 |
| Current Ratio(x) | 1.43 | 1.19 | 1.43 | 3.7 | 3.38 |
| Quick Ratio(x) | 0.52 | 0.45 | 0.68 | 2.99 | 2.74 |
| Interest Cover(x) | 2.78 | 3.48 | 6.84 | 32.88 | 127.65 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.02 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 17% | 0% | 0% |
| Operating Profit CAGR | 12% | 47% | 0% | 0% |
| PAT CAGR | 10% | 77% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 137% | NA% | NA% | NA% |
| ROE Average | 18% | 25% | 23% | 23% |
| ROCE Average | 24% | 27% | 23% | 23% |
Accent Microcell Ltd.
314, Shangrilla Arcade Shyamal Cross Road Anandnagar Road, Satellite
Accent Microcell Ltd.
Corporate Capital Ventures Pvt Ltd.
Accent Microcell Ltd.
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.
For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.
Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.
Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.
Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.